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Abstract
Background: Fetal growth restriction is associated with significantly increased risks of neonatal
death and morbidity and with susceptibility to hypertension, cardiovascular disease and NIDDM
later in life. Human birth weight has a substantial genetic component, with at least a quarter of the
variation attributable to additive genetic effects.
Methods: One hundred twenty-five subjects (83 control and 42 case) were selected using
stringent inclusion/exclusion criteria. DNA sequencing was used to identify 26 single nucleotide
polymorphisms in the pituitary growth hormone gene (GH1) at which all subjects were genotyped.
Association with fetal growth restriction was tested by logistic regression for all sites with minor
allele frequencies greater than 5%.
Results: Logistic regression identified significant association with fetal growth restriction of C
alleles at sites -1 and +3 (relative to the start of transcription) that are in complete linkage
disequilibrium. These alleles are present at higher frequency (6% vs. 0.4%) in fetal growth restricted
subjects and are associated with an average reduction in birth weight of 152 g in normal birth
weight and 97 g in low birth weight subjects.
Conclusions: There is suggestive association between fetal growth restriction and the presence
of C alleles at sites -1 and +3 of the pituitary growth hormone gene.
Background
Fetal growth restriction (FGR) is a major risk factor for ill-
ness in the perinatal period and throughout life, with the
smallest 7.5 percent of infants accounting for two-thirds
of infant deaths [1]. Term, low birth weight infants are at
least five times more likely to die in the first year [2,3] and
are second only to premature infants in their rates of mor-
bidity and mortality [4]. FGR infants have an increased
frequency of hypoglycemia, hypothermia, polycythemia,
neurodevelopmental deficits, and cerebral palsy [5]. Later
in life, individuals born FGR are at elevated risk of hyper-
tension, cardiovascular disease, and non-insulin depend-
ent diabetes [6]. For example, FGR increases the risk for
adult onset of non-insulin dependent diabetes two- to
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FGR early in gestation has enormous potential to reduce
childhood and adult illness.
It is difficult to distinguish the genetic and environmental
components of human birth weight variation, but recent
studies support a major genetic component to birth
weight variation. Clausson et al.'s [9] study of the off-
spring of female dizygotic and monozygotic twins (2,009
twin pairs) estimated heritability for human birth weight
of 42%, although the confounding influence of shared
environmental effects must be considered. In a study of
3,562 captive macaques that minimized environmental
heterogeneity, Ha et al. [10] estimated a total heritability
for birth weight of 51%, with an additive genetic compo-
nent of 23%. These findings demonstrate that compara-
tively simple and readily identifiable genetic factors
influence birth weight. In concert with this recent
research, FGR tends both to cluster in families and to recur
in successive generations [11-14].
The five genes of the human growth hormone locus reside
within about 45 kb on chromosome 17 [15]. Pituitary
growth hormone (GH1) is by far the most thoroughly
studied of the genes and lies at the 5' end of the cluster.
The remaining four genes, placental growth hormone
(GH2) and three chorionic somatomammotropins (CS1,
CS2, and pseudogene CS5 or CSHP1), are expressed only
from the placenta. The promoter region of GH1 is unusu-
ally polymorphic, with 16 SNPs having been identified in
a span of 535 bp [16-18]. Most of these SNPs occur at the
comparatively small number of sites that exhibit sequence
differences among the five genes of the GH locus, and this
has been interpreted as evidence of gene conversion
[16,19].
Here we use DNA sequencing to identify and to determine
the frequencies of both 12 newly-identified single nucle-
otide polymorphisms (SNPs) in the promoter and coding
region of the GH1 gene and 15 previously reported SNPs
[16,18]. Using a case-control design, we identify two SNPs
in complete linkage disequilibrium near the start of tran-




DNA was extracted from placental tissue from 125 live
births (83 normal birth weight, 42 low birth weight) at
Baystate Medical Center (Springfield, MA) in a case-con-
trol study of the genetic predisposition to fetal growth
restriction. All subjects were Caucasian, both Hispanic
and non-Hispanic. Classification of newborns as fetal
growth restricted (or IUGR, intrauterine growth retarded)
followed the definition of the American College of Obste-
tricians and Gynecologists as those newborns below the
10th percentile of size for gestational age [20]. Our cut-off
of 2,500 g at term (>37 weeks gestation) corresponds to
the lowest 7.5 percentile of all US Caucasian deliveries, or
the lowest 10th percentile of female and lowest 6.5 percen-
tile of male deliveries [21]. Stringent inclusion/exclusion
criteria (Table 1) were employed by a placental patholo-
gist (TKB) to reduce nongenetic contributors to birth
weight variation. Ethical approval to conduct this study
was obtained from the Human Subjects Institutional
Review Board of the University of Massachusetts.
Polymerase chain reaction (PCR) and sequencing
The region from -624 (relative to the start of transcription;
GenBank accession J03071) to +1,726 (197 nucleotides
after the termination codon) of GH1 was amplified in two
overlapping fragments: -624 to +541 (GHN-1F 5'
AGGGACCTGGGGGAGCCCCAGCAA 3', GHN-1R 5'
TCACCCCTTCCTGCCACCCCTGAT 3') and +450 to
+1,726 (GHN-2F 5' CCATCGTCTGCACCAGCTGGCCTT
3'; GHN-2R 5' GCCCTACAGGTTGTCTTCCCAACT 3').
Approximately 50 ng of DNA was used as a template in a
polymerase chain reaction with 30 cycles of 95°C (1
minute), 62°C (1 minute), and 72°C (2 minutes 30 sec-
onds). PCR products were purified from agarose using a
QIAquick PCR Purification kit (Qiagen) and sequenced
directly with BigDye v2.0 chemistry (Applied Biosystems)
and run on either an ABI Prism 377 or 3100 automated
DNA sequencer. PCR products were sequenced with the
PCR primers and additional internal primers: 5' AAG-
Table 1: Inclusion and exclusion criteria for the study of fetal 
growth restriction
Inclusion Criteria
≥ 37 weeks gestation (full-term)
Mother 17–35 years old
Singleton pregnancy
Case (fetal growth restricted): <2,500 g birth 
weight
Control: 3,000 to 4,000 g birth weight
Exclusion Criteria
Karyotypic abnormalities, including confined 
placental mosaicism
Placental abnormalities




Type 1, Type 2 or gestational diabetes
Meconium staining
Uterine infection
Maternal chronic illnesses (i. e., hypertension, 
AIDS, hepatitis, endocrinological)
Known illicit drug use
Rh diseasePage 2 of 7
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and the nucleotide present at the homologous site in other members of the human GH locus
Frequency GH1 paralogs
Position* Alleles This Study Horan et al. CS-5 CS-1 GH2 CS-2 Categorization Function**
-580 A 0.985 A A A A Constant
G 0.015
-476 A 0.012 0.013 A G A G Variant
G 0.988 0.987
-360 A 0.972 G G G G Variant
G 0.028
-352 G 0.012 T G G G Variant
T 0.988
-308 G 0.732 0.753 T C T C Variant
T 0.268 0.247
-301 G 0.732 0.753 T T T T Variant
T 0.268 0.247
-278 G 0.628 0.601 T A T A Variant NF1
T 0.372 0.399
-168 C 0.024 0.019 T C T C Variant
T 0.976 0.981
-75 A 0.900 0.886 G A G A Variant PIT-1
G 0.100 0.114
-57 G 0.687 0.633 G T A T Variant Vitamin D Receptor
T 0.313 0.367
-31 G 0.882 0.867 G G - G Variant Vitamin D Receptor
- 0.118 0.133
-6 A 0.565 0.588 A G A G Variant Transcription Start
G 0.435 0.412
-1 A 0.847 0.932 C T A T Variant Transcription Start
C 0.044 0.003
T 0.109 0.065
3 C 0.044 0.003 C G G G Variant Transcription Start
G 0.956 0.997
16 A 0.976 0.981 G A A A Variant 5' UTR
G 0.024 0.019
25 A 0.980 0.981 C A A A Variant 5' UTR
C 0.020 0.019
59 G 0.072 0.049 G G G G Variant 5' UTR
T 0.928 0.951
69 A 0.968 G C G G Variant Thr/Ala
G 0.032
124 A 0.988 G A G A Variant Intron
G 0.012
128 A 0.988 C C T C Variant Intron
T 0.012
140 A 0.004 G G G G Constant Intron
G 0.996
144 A 0.012 G G G G Constant Intron
G 0.988
281 C 0.024 T C C C Variant Intron
T 0.976
596 C 0.986 T T T T Variant Intron
T 0.014
1070 A 0.004 G G G G Constant Synonymous
G 0.996
1169 A 0.331 T T T T Constant Intron
T 0.669
* Relative to the start of transcription
** Polymorphisms in known transcription factor binding sites are shown. Site +69 is part of the signal peptide.Page 3 of 7
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GCACAAGCCCGTCAGTGGCC 3', -108 to -89; 5'
GGATTTTAGGGGCGCTTACC 3', +71 to +90; 5' CATCTC-
CCTGCTGCTCATC 3', +931 to+949; 5' GCGCTTGGGY-
ACTGTTCCCT 3', +1280 to +1299.
Single nucleotide polymorphism (SNP) genotyping
Sequence traces were aligned and assembled into contigs
by the program Polyphred [22]. Contigs were viewed in
either the program Consed [23] or Sequencher (Gene
Codes Corp.) and polymorphisms confirmed visually.
Twenty-six polymorphic sites were identified (Table 2),
including all of the sites identified by Horan et al. [18] in
154 British military recruits with the exception of site -339
which had a minor allele (deletion of G) frequency of
3.6% in their study.
Statistical analyses
The five genes of the human growth hormone locus
exhibit high sequence similarity, and the paralogous
regions corresponding to the portion of GH1 sequenced
in this study (-624 to +1,726) were multiply aligned.
Nucleotide positions (Table 2) were designated as invari-
ant if all five genes had the same nucleotide or the four
paralogs of GH1 were identical and matched the major
allele at that site in GH1. This categorization explicitly
assumes that only the minor alleles in GH1 are the prod-
uct of gene conversion and that minor alleles not
observed in paralogs of GH1 are the result of unique
mutations. The proportion of GH1 polymorphisms at
invariant versus variant sites was compared by Fisher's
Exact Test to determine if there was an over-representation
of polymorphic sites among variant sites.
Logistic regression, using FGR status as the outcome, was
performed on gestational age and genotypes at sites with
a minor allele frequency above 5% (Table 3). Sites -301
and -308 (relative to the start of transcription) are in com-
plete linkage disequilibrium and the minor C alleles at
sites -1 and +3 are in complete linkage disequilibrium.
Therefore, sites -301 and +3 were excluded from logistic
regression to avoid multicollinearity. Based on the results
from logistic regression, separate ANOVA (Table 4) was
performed on gestational age and the AA versus AC geno-
types at site -1 within low birth weight and within normal
birth weight subjects. Empirical p values for the F statistic
for the genotypic effect, corrected for multiple compari-
sons, were determined by 2,000 random permutations of
the genotypic data [24]. All statistical analyses were per-
formed using the Stata program (Stata Corp., College Sta-
tion, TX).
Results
Polymorphism in the GH1 gene
Among the 125 subjects sequenced from -624 to +1,726
of the GH1 gene, 26 polymorphic sites were identified
(Table 2). These included all but one of the 15 sites char-
acterized by Horan et al. (2003). In the region of overlap
between the two studies, we failed to detect variation at
site -339, where there is a minor allele deletion of a single
nucleotide with frequency 3.6% in British army recruits,
and identified two additional variants at sites -360 and -
352 with minor allele frequencies 2.8% and 1.2%, respec-
tively. Therefore, the discrepancies between the two stud-
ies in the identification of SNPs can most likely be
ascribed to sampling error. Outside the region surveyed by
Horan et al. (2003), we detected 10 additional
polymorphisms. All of these had minor allele frequencies
≤ 3.2%, except an intron four polymorphism at site +1169
with a minor allele frequency of 33.1%. In general,
polymorphisms in the promoter of GH1 tend to be more
densely clustered and exhibit higher minor allele frequen-
cies than in the transcribed region.
Table 3: Logistic regression on FGR status based on gestational age and SNP genotype for GH1 polymorphisms with minor allele 
frequency greater than 5%
Variable Odds Ratio 95% CI Z Score P-value
Gestational Age 0.42 0.26–0.66 -3.75 <0.001
-308 2.66 0.54–13.19 1.20 0.23
-278 1.62 0.27–9.80 0.52 0.60
-75 1.70 0.55–5.23 0.93 0.35
-57 3.34 0.62–18.12 1.40 0.16
-31 0.85 0.27–2.65 -0.29 0.78
-6 2.11 0.66–6.74 1.26 0.21
-1 A/T 0.76 0.23–2.44 -0.47 0.64
-1 A/C 0.10 0.01–0.77 -2.21 0.03
+59 1.48 0.32–6.95 0.50 0.62
+1169 1.05 0.38–2.95 0.10 0.92Page 4 of 7
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An alignment of the region of GH1 sequenced in this
study with the paralogous sequences of placental growth
hormone and chorionic somatomammotropins indicated
that there are 1,979 invariant sites and 293 variant sites
(excluding 78 sites that could not be unambiguously
aligned), as defined in the methods. Of the invariant sites,
5 are polymorphic in GH1, while 21 of the variant sites
are polymorphic. A comparison of the proportion of pol-
ymorphic sites at invariant and variant sites by Fisher's
Exact Test is highly significant (P <<0.001). This result
indicates that there is a strong bias for polymorphisms in
GH1 to occur at the minority of sites that exhibit sequence
divergence among the paralogous genes. The high corre-
spondence between the sequence of minor alleles in GH1
and nucleotides present in paralogs of GH1 supports pre-
vious assertions that the unusually high polymorphism of
the GH1 gene is driven by gene conversion [16,18].
A proportion of this bias may be explained by selective
constraint, in that sites that are polymorphic within GH1
may be under less selective constraint and thus more free
to exhibit sequence divergence among paralogs. However,
to entirely explain the bias towards polymorphism at sites
of divergence, one must assume that about 1,804 (91%)
of the invariant sites are selectively constrained and not
free to vary. Given that a substantial proportion (814 bp,
~36%) of the sequence surveyed in this study is composed
of introns, this assumption seems unreasonable.
Association with fetal growth restriction
Logistic regression (Table 3) was performed on gestational
age and SNPs with minor allele frequencies greater than
5%, excluding sites -301 and +3 because they are in com-
plete linkage disequilibrium with other sites, to identify
associations with fetal growth restriction. Gestational age
was significant because the FGR subjects exhibit a slightly
younger average estimate of gestational age (38.1 vs. 39.1
weeks, t = 4.9, p < 0.0001; gestational ages rounded to
nearest week). However, even accounting for the effect of
gestational age, the C allele at site -1 was significantly
associated with FGR in the combined regression.
However, this allele did not retain significance in a regres-
sion on only gestational age (p < 0.001) and the A/C pol-
ymorphism at site -1 (p = 0.242).
Although the A/C polymorphism at site -1 was not signif-
icant in a reduced model, we decided to investigate this
site for three reasons. First, the C allele at site -1 is in com-
plete linkage disequilibrium with C at site +3. Second,
both of these sites are located at the start of transcription,
making them good candidates for affecting the level of
transcription of GH1. Third, the only paralog that shares
C at these sites is CS-5, a pseudogene, consistent with the
possibility that C at sites -1 and +3 is disadvantageous.
The C allele at both sites exhibits a much higher frequency
in low birth weight (6%) versus normal birth weight
(0.4%) subjects. Restricting examination only within the
normal or low birth weight subjects, the AC genotype is
associated with an average reduction of birth weight of
152 g and 97 g in normal and low birth weight subjects,
respectively. However, this difference does not achieve
significant in an ANOVA on the A/C polymorphism and
gestational age (Table 4).
Discussion
Birth weight in humans and other primates exhibits sub-
stantial heritability [9-13]. Although a suite of environ-
mental and genetic/karyological insults are known to
cause fetal growth restriction, perhaps as many as 40% of
FGR cases have no known etiology [25]. Therefore, identi-
fication of the underlying genetic variants that predispose
to FGR could have significant medical significance if it
allows us to identify early in gestation those pregnancies
that are at increased risk of growth retardation. A logical
place to begin such a search is among those genes that are
known to be major regulators of fetal growth and to
exhibit significant differences in circulating protein con-
centrations between normal and FGR pregnancies, such as
the members of the growth hormone-prolactin and insu-
lin-IGF families of hormones, receptors, and binding pro-
teins. Here, we use a stringently selected set of subjects to
Table 4: ANOVA on A/C genotypes at site -1 and gestational age in normal and low birth weight subjects
Normal Birth Weight Low Birth Weight
Site -1 Gestational Age Site -1 Gestational Age
Mean AA 3382.8 2287.9
Mean AC 3230.2 2190.4
ANOVA F 3.75 4.55 3.12 2.25
P-value 0.056* 0.002 0.073* 0.099
* Empirical P value corrected for multiple testing determined by 2,000 random permutations of the genotypic data [24]Page 5 of 7
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growth restriction.
Adjusted for gestational age, the C alleles at sites -1 and +3
of the GH1 gene appear to be associated with reduction in
birth weight. The marginal significance of these results
may be the result of several factors. First, we examined 125
total subjects, roughly one-third of them FGR, and this
number may give inadequate statistical power to identify
weak genetic effects. Second, the C allele is low frequency,
providing a small number of heterozygotes for the allele
and no homozygotes. It is worth noting that among nor-
mal birth weight subjects we observed a very similar fre-
quency for the C allele as Horan et al. (2003) did among
British army recruits (0.4% vs. 0.3%) but that among the
low birth weight subjects the frequency of the C allele is
substantially higher (6%). Comparing all the other allele
frequencies (Table 2) between the two studies of Cauca-
sian populations, no other allele shows such a large mag-
nitude of difference, although the proportional difference
in frequency of C at -1 and +3 may be somewhat distorted
by sampling error at low allele frequencies. Third, FGR
undoubtedly has a heterogeneous genetic etiology, and it
may be unlikely to find any genetic variant that accounts
for more than a small proportion of cases.
If the C allele at -1 and +3 exhibits true association with
FGR, it unfortunately may be very difficult to determine if
the effect is due to one or both sites because they are in
complete linkage disequilibrium. Nevertheless, the pres-
ence of both alleles at the start of GH1 transcription pro-
vides both variants with a biologically plausible
possibility to affect the level of transcription of GH1.
Future work should be devoted to examining the effect of
these alleles on transcription levels both alone and in
combination. Site -1 is somewhat unique among single
nucleotide polymorphisms in that three alternate alleles
exist at that site (the major allele A and the minor alleles
C and T). There are two possible explanations for this
observation. First, site -1 could be a hotspot for nucleotide
mutation, with transversions from A to C/T occurring
often. Second, GH1 may be the recipient of gene conver-
sion events from more than one paralog within the GH
locus. Among the four other genes of the GH locus, all
three alleles observed at site -1 occur (Table 2). Given the
predominant effect that gene conversion [16,18] appears
to have on the patterns of nucleotide polymorphism in
the GH1 gene, the latter explanation may be more
plausible.
It must be pointed out that the common wisdom is that
GH1 plays no role in regulating fetal growth because the
GH receptor is expressed fairly late in gestation and
because anencephalic infants or those born without a
pituitary achieve nearly normal length [26]. Importantly,
we restricted our study to full term deliveries. It is possible
that late in gestation, when fetal GH1 is expressed and
GHR receptors are present in a wide variety of fetal tissues,
pituitary growth hormone begins to have a growth stimu-
latory role sufficient to account for the 90–150 g differ-
ence in birth weight between genotypes for the A/C
polymorphism at -1 and +3 that we observed.
Conclusions
In a stringently selected set of subjects, C alleles at sites -1
and +3 relative to the start of transcription of GH1 have a
higher frequency (0.4% vs. 6%) in fetal growth restricted
newborns. These two alleles are in complete linkage dise-
quilibrium and their presence is associated with a reduc-
tion in birth weight of 152 g in term, normal birth weight
subjects and 97 g in term, low birth weight (<2,500 g)
subjects. In combination with environmental, behav-
ioural and other genetic factors, these alleles may contrib-
ute to fetal growth restriction.
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